Chembio Diagnostics, Inc.

NasdaqCM:CEMI Stock Report

Market Cap: US$16.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Chembio Diagnostics Management

Management criteria checks 2/4

Key information

Richard Eberly

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage28.56%
CEO tenure3.1yrs
CEO ownership1.0%
Management average tenure2.2yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 06

Chembio gets $3.2M contract from CDC to develop rapid test for syphilis

Chembio Diagnostics (NASDAQ:CEMI) said it was awarded a $3.2M contract from the Centers for Disease Control and Prevention (CDC) to develop and validate a rapid point-of-care (POC) diagnostic test for syphilis. Chembio will develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II. The assay will be intended to simultaneously and separately detect treponemal and nontreponemal IgM and IgG antibodies, the company said in Sept. 6 press release. "We are excited to continue expanding our core sexually transmitted disease portfolio with the syphilis screen and confirm assay,” said Javan Esfandiari, chief science and technology officer, Chembio. CEMI +3.55% to $0.67 premarket Sept. 6
Seeking Alpha • Aug 16

Chembio stock rises 13% amid plans to develop rapid test for monkeypox

Chembio Diagnostics (NASDAQ:CEMI) said it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. The company added that it is exploring the technical requirements for test development using its technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners. "We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are assessing the market needs, timing, regulatory pathway and investment required to develop a test," said Chembio's President and CEO Richard Eberly. CEMI +12.64% to $0.98 premarket Aug. 16
Analysis Article • Nov 30

Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 08

Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher

Shareholders in Chembio Diagnostics, Inc. ( NASDAQ:CEMI ) may be thrilled to learn that the analysts have just...
Analysis Article • Jul 22

Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Apr 07

Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jan 16

Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?

If you want to know who really controls Chembio Diagnostics, Inc. ( NASDAQ:CEMI ), then you'll have to look at the...
Analysis Article • Dec 12

Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

CEO Compensation Analysis

How has Richard Eberly's remuneration changed compared to Chembio Diagnostics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022US$2mUS$460k

-US$23m

Sep 30 2022n/an/a

-US$36m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$38m

Dec 31 2021US$2mUS$477k

-US$34m

Sep 30 2021n/an/a

-US$27m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$1mUS$315k

-US$26m

Compensation vs Market: Richard's total compensation ($USD1.61M) is above average for companies of similar size in the US market ($USD767.83K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Eberly (61 yo)

3.1yrs
Tenure
US$1,610,406
Compensation

Mr. Richard L. Eberly serves as the President and Chief Executive Officer at Chembio Diagnostics, Inc. since March 16, 2020 and has been its Director since May 02, 2020. He joined Chembio in March, 2020. H...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Eberly
President3.1yrsUS$1.61m1.03%
$ 171.6k
Lawrence Steenvoorden
Executive VP1.3yrsUS$1.05m0.15%
$ 24.4k
Javan Esfandiari
Executive VP and Chief Scientific & Technology Officer19.3yrsUS$765.96k0.50%
$ 84.2k
Paul Angelico
Executive VP & COO3yrsno data0.021%
$ 3.6k
Stella Rivera
Vice President of Human Resources1.4yrsno datano data
Charles Caso
Senior Vice President of Global Commercial Operations1.3yrsno data0.021%
$ 3.6k
2.2yrs
Average Tenure
59yo
Average Age

Experienced Management: CEMI's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Eberly
President2.9yrsUS$1.61m1.03%
$ 171.6k
Leslie Teso-Lichtman
Independent Directorless than a yearUS$143.43kno data
John Potthoff
Independent Director4.9yrsUS$100.31k0.15%
$ 24.6k
Katherine Davis
Independent Chairperson15.9yrsUS$123.89k0.31%
$ 52.0k
David William Acheson
Independent Director2.3yrsUS$91.56k0.040%
$ 6.7k
David Bespalko
Independent Director2.1yrsUS$94.06k0.031%
$ 5.2k
2.6yrs
Average Tenure
64yo
Average Age

Experienced Board: CEMI's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/27 06:51
End of Day Share Price 2023/04/27 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chembio Diagnostics, Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Mark MassaroCanaccord Genuity
Per OstlundCraig-Hallum Capital Group LLC